Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Phase 1
30
about 4.1 years
18+
1 site in MO
What this study is about
Researchers are testing whether adding CYT107 to standard treatment after autologous hematopoietic cell transplant can help clear tumors, improve immune function, and reduce infections in people with multiple myeloma. The trial will compare patients who receive CYT107 plus melphalan and AHCT to those who only receive melphalan and AHCT.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Melphalan
- 2.Take Recombinant glycosylated human interleukin-7
- 3.Undergo Autologous hematopoietic cell transplant
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
melphalan
injection, intravenous
Primary: Rate of non-hematologic grade ≥3 CYT107 treatment-related AEs (excluding expected transplant-related AEs or AEs attributed to melphalan and ASCT) according to CTCAE v5
Secondary: Rate of response by IMWG of ≥ complete response (CR)
surgery
Oncology